AbbVie Inc. (ABBV)
If You Wanted To Buy AbbVie and Didn't, There's Still Time To Buy
If you have been or are thinking about getting into AbbVie NYSE: ABBV, there is still time to do so. The AbbVie stock price is in a sustained uptrend and will set new all-time highs repeatedly over time.
AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet.
First-quarter adjusted earnings per share were $2.46 on sales of $13.3 billion, above analysts' expectations.
5 Rock-Solid Passive Income Dividend Aristocrats That Are Reasonably Safe From Tariffs
The driving force behind the recent volatility in the stock and bond markets can be boiled down to one specific item: the threat of tariffs and a global trade war.
Buy Stock in These Healthcare Leaders as Q1 Earnings Approach? ABBV, HCA
The medical sector can provide a defensive hedge against economic uncertainty, and investors may be eyeing AbbVie (ABBV) and HCA Healthcare (HCA) stock ahead of their Q1 reports on Friday, April 25.
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings
Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.
Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment
AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.
The Zacks Analyst Blog Merck and AbbVie
Merck and AbbVie are included in this Analyst Blog.
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
